Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
June 18, 2020

Myovant’s Phase III relugolix trial’s cardiovascular event reduction trend inconclusive

By Victoria Smith

At the beginning of the month, Myovant’s share price skyrocketed 55% after data from its Phase III HERO trial (NCT03085095) comparing relugolix with generic leuprolide were presented at the recent American Society of Clinical Oncology (ASCO) Virtual Meeting.

While experts acknowledged relugolix’s CV event reduction trend is in line with present data in gonadotropin-releasing hormone (GnRH) antagonists, most noted that even taken in totality, analyses thus far are only hypothesis-generating. Read more here.

Related Companies

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU